{"gene":"CSH2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1989,"finding":"The CSH2 (hCS-B) gene is expressed exclusively in placental tissue (not pituitary), as determined by screening pituitary and placental cDNA libraries with gene-specific oligonucleotides. The locus contains five genes with ~95% sequence identity; hCS-B is one of four placenta-specific members of the growth hormone gene cluster on chromosome 17.","method":"cDNA library screening with gene-specific oligonucleotides; full locus sequencing (~66,500 bp)","journal":"Genomics","confidence":"High","confidence_rationale":"Tier 1 / Strong — complete nucleotide sequencing of the locus combined with cDNA library screening using specific oligonucleotide probes, replicated across multiple libraries","pmids":["2744760"],"is_preprint":false},{"year":1991,"finding":"CSH2 (hCS-B) is expressed in placenta-derived choriocarcinoma BeWo cells (but not in JAR or JEG-3 cells, and not pituitary hGH-N), and treatment with 10 nM T3 causes a ~6-fold increase in CSH2 (and hCS-A and hGH-V) mRNA levels; cellular and secreted ~22 kDa protein is increased by T3 treatment as detected by Western blot.","method":"Oligonucleotide-specific Northern blotting of polyadenylated RNA; Western blotting of cellular and secreted protein; T3 treatment of BeWo cells","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RNA and protein detection with gene-specific probes plus hormonal manipulation, single lab but two orthogonal methods","pmids":["1708334"],"is_preprint":false},{"year":1993,"finding":"Treatment of BeWo choriocarcinoma cells with methotrexate (MTX) differentially suppresses CSH2 (hCS-B) and hCS-A relative to hGH-V; after MTX treatment only hGH-V and minor hCS-A transcripts were detected. MTX also blunts the T3-mediated increase in hCS/hGH-V transcripts without altering T3 receptor number or affinity, indicating MTX interferes with T3 responsiveness of the CSH2 gene.","method":"Northern blotting with gene-specific oligonucleotide probes; T3 receptor binding assay; MTX treatment of BeWo cells","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gene-specific RNA detection combined with receptor binding assay, single lab, two orthogonal methods","pmids":["8472847"],"is_preprint":false},{"year":1994,"finding":"The transcriptional activity of the CSH2 (hCS-B) enhancer is mediated by two protein-binding sites, DF-3 and DF-4. Protein f (three polypeptides of ~12–21 kDa identified by UV cross-linking) binds the TEF-1-like motif within DF-4 and is important for placenta-specific activity of the hCS-B enhancer. Mutations in the TEF-1-like motif of DF-4 prevent complex f formation and greatly reduce transcriptional activity in JEG-3 cells.","method":"EMSA (electrophoretic mobility-shift assay); antibody supershift; UV cross-linking; transient expression with TKCAT constructs in JEG-3 cells","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (EMSA, UV crosslinking, functional reporter assay) in single lab","pmids":["7945936"],"is_preprint":false},{"year":1994,"finding":"CSH2 (hCS-L is the pseudogene, not CSH2; this paper concerns hCS-L) — excluded as it is about the hCS-L pseudogene, not CSH2.","method":"N/A","journal":"N/A","confidence":"Low","confidence_rationale":"Excluded — paper is about hCS-L, not CSH2","pmids":["8083227"],"is_preprint":false},{"year":1995,"finding":"The CSH2 (hCS-B) gene, along with hGH-N, requires a multicomponent locus control region (LCR) located ~15 and ~30 kb 5' of hGH-N for high-level, position-independent expression. DNase I hypersensitive sites (HS) common to both pituitary and placenta are required for placental gene expression; individually each set of HS loses physiologic control and tissue specificity, demonstrating synergistic interactions among multiple elements are needed for regulated expression of the hGH/hCS cluster including hCS-B.","method":"DNase I chromatin mapping; transgenic mouse integration of cosmid constructs; position-independence assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic mouse experiments with cosmid constructs combined with DNase I chromatin mapping, multiple independent transgenic lines tested","pmids":["8524268"],"is_preprint":false},{"year":1996,"finding":"The CSH2 (hCS-B) gene enhancer activity in syncytiotrophoblast primary culture is mediated by two elements, DF-3 and DF-4. A syncytiotrophoblast-specific protein binds the 3' part of DF-4, and targeted mutation of this site abolishes DF-4 element activity. The DF-3 element of hCS-B is more active than the homologous DF-3 in hCS-A due to a single naturally occurring base mutation that reduces activity in hCS-A. Replacement of the hCS-B DF-3 with the hCS-A sequence reduces hCS-B enhancer activity. During cytotrophoblast-to-syncytiotrophoblast differentiation in primary culture, hCS enhancers (including hCS-B) are progressively activated.","method":"Transient expression in primary syncytiotrophoblast culture; EMSA; targeted site-directed mutagenesis of enhancer elements","journal":"DNA and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional mutagenesis plus EMSA and primary cell culture, single lab","pmids":["8892756"],"is_preprint":false},{"year":1997,"finding":"hTEF-5 (human TEF family transcription factor) is preferentially expressed in placenta and directly binds to multiple functional enhancer elements (TEF-binding sites) within the CSH2 (hCS-B) gene enhancer, as shown by EMSA and supershift assays. A tandemly repeated TEF-5 binding element in the hCS-B enhancer is bound cooperatively by hTEF-5. The corresponding hCS-A enhancer element is inactivated by a single naturally occurring base mutation that disrupts TEF-5 binding, explaining the differential activity of these two enhancers.","method":"EMSA; antibody supershift with anti-TEA domain monoclonal antibodies; site-directed mutagenesis; cDNA cloning and Northern blotting","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal EMSA/supershift plus mutagenesis establishing transcription factor–DNA interaction mechanism, multiple orthogonal methods","pmids":["9148898"],"is_preprint":false},{"year":1997,"finding":"A 7 bp cAMP- and PMA-responsive element (CRElhCS-A) upstream of hCS-A mediates cAMP/phorbol ester responses, but the homologous sequence upstream of CSH2 (hCS-B), CRElhCS-B, differs by a single nucleotide substitution and shows little or no response to cAMP. Band-shift and Southwestern assays show CRElhCS-A binds a 100 kDa and a 47 kDa protein (related to CREBP and AP-1 respectively), while CRElhCS-B binds only the 47 kDa protein. The 100 kDa protein plays a crucial role in cAMP regulation specific to the hCS-A gene, while the 47 kDa protein is involved in PMA response of both hCS-A and hCS-B genes.","method":"Transient expression assays; EMSA (band-shift); Southwestern blotting","journal":"Journal of molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and Southwestern plus functional reporter assays, single lab, multiple methods","pmids":["9134496"],"is_preprint":false},{"year":2011,"finding":"CCAAT/enhancer-binding protein (C/EBP) binding sites exist in the 80 bp modulatory domain of both the CSH2 (hCS-B) and hCS-A enhancers; an Elk-1 binding site is present in the CS-A enhancer modulatory domain. C/EBPα or C/EBPβ strongly represses CSH2 promoter activity alone but stimulates promoter activity when the hCS-B enhancer is present; the homologous CS-A enhancer sequences cannot relieve this repression. ChIP assays show differential association of C/EBPβ with CS-A and CS-B gene chromatin in human placenta, including differential involvement with their respective enhancers.","method":"EMSA; transient reporter assays in JEG-3 cells; chromatin immunoprecipitation (ChIP) in human placental chromatin","journal":"Journal of molecular endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — EMSA plus functional reporter assays plus ChIP in native chromatin, multiple orthogonal methods in single study","pmids":["21737519"],"is_preprint":false},{"year":2015,"finding":"CSH2 mRNA displays an alternative splicing pattern in somatotroph pituitary adenomas. CSH2 isoform 3 is associated with a dense granulation pattern and an epithelial phenotype (high ESRP1 and E-cadherin expression) and is associated with reduced serum GH and IGF-I levels after somatostatin analog (SA) treatment, linking CSH2 splicing to treatment response.","method":"RNA sequencing (RNAseq); qRT-PCR in 65 somatotroph adenomas","journal":"Neuro endocrinology letters","confidence":"Low","confidence_rationale":"Tier 3 / Weak — RNA-seq and qRT-PCR correlation in clinical samples; no direct mechanistic experiment on the CSH2 protein itself","pmids":["26071582"],"is_preprint":false},{"year":2015,"finding":"Expression of placental CSH2 (hCS-B) and hCS-A genes in JEG-3 placental tumor cells is increased >10-fold by sequential treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (azadC) followed by the histone deacetylase inhibitor trichostatin A (TSA), but not by TSA alone or by reversing the treatment order. This is accompanied by increased histone H3/H4 acetylation at the hCS 3' enhancer sequences and LCR, indicating that DNA methylation restricts chromatin accessibility at these regulatory regions required for CSH2 expression.","method":"qRT-PCR of hCS-A, CS-B, GH-V RNA; ChIP for hyperacetylated H3/H4; luciferase reporter assays with hCS promoter constructs in JEG-3 and nonplacental cells","journal":"BioResearch open access","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus RNA quantification plus functional reporter assays using epigenetic inhibitors, single lab","pmids":["26634190"],"is_preprint":false},{"year":2018,"finding":"Pre-pregnancy maternal obesity disrupts the placenta-specific chromosomal architecture at the hGH/CS locus, including interactions between upstream locus control region hypersensitive sites (HS III-V) and the CSH2 (hCS-B) and hCS-A gene promoters. In lean women, chromosome conformation capture detects preferential interactions between HS III-V and hCS (but not hGH) promoters; in obese women this architecture is disrupted and HS III preferentially interacts with the hGH-N promoter. Insulin treatment in obese women with gestational diabetes partially recapitulates the lean chromosomal architecture and positively affects hCS production. Decreased hCS levels in obesity are accompanied by reduced RNA polymerase II and C/EBPβ association with hCS promoter and enhancer sequences.","method":"Chromosome conformation capture (3C) assay; ChIP for RNA Pol II and C/EBPβ; quantitative PCR for hCS RNA levels","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — 3C chromatin architecture plus ChIP plus RNA quantification across multiple human tissue samples with physiological and pharmacological conditions","pmids":["29763375"],"is_preprint":false},{"year":2018,"finding":"Silencing CSH2 by RNAi in human sperm (in a model using hamster oocytes fertilized by HBV-transfected human sperm) causes a significant decrease in transcriptional levels of HBV s and x genes in the resulting embryo, indicating that CSH2 expression in sperm/embryo positively regulates HBV gene transcription.","method":"RNAi knockdown of CSH2 in human sperm; qRT-PCR of HBV s and x gene transcription in embryos derived from in vitro fertilization","journal":"Asian journal of andrology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (RNAi + qRT-PCR), unusual experimental system, no mechanistic pathway for CSH2 action established","pmids":["29111540"],"is_preprint":false},{"year":2014,"finding":"CSH2 mRNA is detectable in breast cancer cell lines and some primary carcinomas; however, when CSH1/CSH2 mRNA was efficiently suppressed by shRNA, the immunoreactive 'hPL' band detected by certain commercial antibodies was not abolished, demonstrating those antibodies are non-specific. Custom monoclonal antibodies detected hPL protein only when mRNA was increased several thousand-fold, establishing that CSH2 mRNA is present in breast cancer but is not translated into protein under normal conditions.","method":"shRNA knockdown of CSH mRNA; Western blotting with multiple polyclonal and monoclonal antibodies (commercial and custom); immunohistochemistry; qRT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — shRNA knockdown combined with orthogonal antibody validation (multiple antibodies including custom) and qRT-PCR, single lab","pmids":["24475273"],"is_preprint":false},{"year":2025,"finding":"The PEG3/PW1 transcription factor binds to hypersensitive sites (HS III-V) within the hPL/CSH locus control region in CTB-like JEG-3 cells, and CSH2 (hPL-B) transcript levels increase upon PEG3 knockdown. In term placenta from obese women, PEG3 binding at placenta-specific HS IV is increased and hPL RNA levels are decreased; in obese women with insulin-treated gestational diabetes, PEG3 binding is reduced and hPL expression is increased. Chromosome conformation capture reveals distinct hPL gene domain interactions that are modified with obesity but largely reversed in O/GDM+Ins, correlating with PEG3 binding levels.","method":"ChIP for PEG3 at LCR hypersensitive sites; siRNA knockdown of PEG3 in JEG-3 cells; chromosome conformation capture (3C); qRT-PCR of hPL/CSH2 RNA levels in human placenta stratified by obesity/GDM status","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP plus functional knockdown plus 3C chromatin architecture, preprint, single lab","pmids":[],"is_preprint":true},{"year":2025,"finding":"P sequences located upstream of all four placental hGH/PL genes (including CSH2/hPL-B) but not hGH-N repress hPL-A promoter activity in transfected pituitary GC cells and bind a forkhead box A1/nuclear factor-1 transcription factor complex proposed to act as a repressor in human pituitary chromatin. The LCR HS III interacts with P sequences in human pituitary chromatin as detected by chromosome conformation capture, suggesting a mechanism by which P sequences prevent CSH2 and other placental hGH/PL genes from being expressed in the pituitary.","method":"Transient transfection reporter assays in pituitary GC cells; EMSA for transcription factor binding to P sequences; chromosome conformation capture (3C) in human pituitary chromatin","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay plus EMSA plus 3C, single lab","pmids":["40362658"],"is_preprint":false},{"year":2016,"finding":"In cultured bovine trophoblast cells, leptin supplementation increases CSH2 (chorionic somatomammotropin hormone 2/placental lactogen) transcript abundance at both 6 h and 24 h across all doses tested (10–250 ng/mL), while it does not affect interferon-tau (IFNT) expression or cell proliferation, indicating that leptin specifically upregulates CSH2 transcription in trophoblast cells.","method":"Graded recombinant bovine leptin treatment of cultured bovine trophoblast cells; qRT-PCR measurement of CSH2 and other transcripts; cell proliferation assay","journal":"Domestic animal endocrinology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single method (qRT-PCR) in bovine cell culture, no mechanistic pathway for leptin-CSH2 signaling defined","pmids":["27743526"],"is_preprint":false}],"current_model":"CSH2 (hCS-B/hPL-B) encodes a placenta-specific member of the human growth hormone/chorionic somatomammotropin gene cluster whose expression is restricted to syncytiotrophoblast by a multicomponent locus control region (LCR) ~15–30 kb upstream; placenta-specific transcription is driven by a downstream enhancer whose activity depends on cooperative binding of hTEF-5 to tandem TEF-binding elements and a syncytiotrophoblast-specific factor at the DF-3/DF-4 sites, modulated by C/EBPβ binding; chromatin accessibility at the LCR and enhancer is further gated by DNA methylation and histone acetylation status; chromosomal architecture linking LCR hypersensitive sites to CSH2 promoters is disrupted by maternal obesity and can be partially restored by insulin; PEG3 binding to LCR sequences represses CSH2 expression, and P sequences upstream of CSH2 prevent its expression in the pituitary; CSH2 mRNA is present in breast cancer but is not translated into protein at physiological levels."},"narrative":{"mechanistic_narrative":"CSH2 (hCS-B/hPL-B) is a placenta-specific member of the human growth hormone/chorionic somatomammotropin gene cluster on chromosome 17, expressed exclusively in placental tissue and restricted from the pituitary despite ~95% sequence identity among the five clustered genes [PMID:2744760]. Its high-level, position-independent expression depends on a multicomponent locus control region (LCR) located ~15 and ~30 kb 5' of hGH-N, where DNase I hypersensitive sites shared between pituitary and placenta act synergistically to enforce regulated, tissue-specific output [PMID:8524268]. Placenta-specific transcription is driven by a downstream enhancer composed of DF-3 and DF-4 elements: the placenta-restricted factor hTEF-5 binds cooperatively to a tandemly repeated TEF-binding motif within DF-4, and a syncytiotrophoblast-specific protein binds the 3' portion of DF-4, with naturally occurring single-base differences from the paralogous hCS-A enhancer explaining the differential activity between the two genes [PMID:7945936, PMID:8892756, PMID:9148898]. C/EBPβ modulates this system, repressing the CSH2 promoter alone but stimulating it in the context of the hCS-B enhancer, and associates with CS-B chromatin in native placenta [PMID:21737519]. Access to the LCR and enhancer is gated epigenetically, as combined DNA-demethylation and histone-deacetylase inhibition de-represses CSH2 with concomitant H3/H4 hyperacetylation at the 3' enhancer and LCR [PMID:26634190]. The chromosomal architecture linking LCR hypersensitive sites (HS III-V) to the CSH2 promoter is physiologically regulated: it is disrupted by maternal obesity and partially restored by insulin, with PEG3/PW1 binding to the LCR repressing CSH2 and tracking inversely with hPL expression [PMID:29763375]. P sequences upstream of the placental genes recruit a forkhead/NF-1 repressor complex that, via LCR HS III contacts, prevents CSH2 expression in the pituitary [PMID:40362658].","teleology":[{"year":1989,"claim":"Established that CSH2 is a distinct, placenta-restricted member of a highly homologous five-gene cluster, defining the central regulatory problem of how near-identical genes achieve tissue-specific expression.","evidence":"cDNA library screening with gene-specific oligonucleotides and full locus sequencing","pmids":["2744760"],"confidence":"High","gaps":["Does not identify the cis-elements or factors enforcing placental restriction","No protein-level characterization"]},{"year":1991,"claim":"Showed CSH2 is hormonally regulated and produces a ~22 kDa secreted protein, demonstrating a cellular model (BeWo) for inducible expression.","evidence":"Oligonucleotide-specific Northern and Western blotting with T3 treatment of BeWo cells","pmids":["1708334"],"confidence":"Medium","gaps":["Mechanism of T3 responsiveness at the CSH2 locus not mapped","Cell-line restriction (BeWo only) unexplained"]},{"year":1993,"claim":"Demonstrated that methotrexate selectively suppresses CSH2 and blunts its T3 response without altering T3 receptor levels, indicating regulation acts at the level of locus responsiveness rather than receptor abundance.","evidence":"Northern blotting, T3 receptor binding assay, and MTX treatment of BeWo cells","pmids":["8472847"],"confidence":"Medium","gaps":["Molecular target of MTX interference not identified","No link to specific cis-elements"]},{"year":1994,"claim":"Localized placenta-specific enhancer activity to DF-3 and DF-4 elements and identified a TEF-1-like motif in DF-4 bound by protein f, establishing the first cis/trans determinants of CSH2 enhancer function.","evidence":"EMSA, UV cross-linking, supershift, and TKCAT reporter assays in JEG-3 cells","pmids":["7945936"],"confidence":"Medium","gaps":["Identity of protein f not molecularly defined","Syncytiotrophoblast-specific factor not yet characterized"]},{"year":1995,"claim":"Defined a multicomponent LCR ~15-30 kb upstream as required for high-level, position-independent CSH2 expression, showing that multiple hypersensitive sites act synergistically rather than independently.","evidence":"DNase I chromatin mapping and transgenic mouse integration of cosmid constructs","pmids":["8524268"],"confidence":"High","gaps":["Trans-acting factors at LCR HS sites not identified","Mechanism of synergy and promoter selection unresolved"]},{"year":1996,"claim":"Resolved why CSH2 and hCS-A enhancers differ in strength, attributing it to a single base difference in DF-3 and a syncytiotrophoblast-specific factor at DF-4, and linked enhancer activation to cytotrophoblast-to-syncytiotrophoblast differentiation.","evidence":"Transient expression in primary syncytiotrophoblast culture, EMSA, and site-directed mutagenesis","pmids":["8892756"],"confidence":"Medium","gaps":["Syncytiotrophoblast-specific factor identity unknown","Differentiation signal driving enhancer activation not defined"]},{"year":1997,"claim":"Identified hTEF-5 as a placenta-enriched factor binding cooperatively to a tandem TEF element in the CSH2 enhancer, providing a molecular basis for differential enhancer activity via a TEF-5-disrupting mutation in hCS-A.","evidence":"EMSA, anti-TEA-domain supershift, mutagenesis, and cDNA cloning/Northern blotting","pmids":["9148898"],"confidence":"High","gaps":["hTEF-5 not the sole syncytiotrophoblast determinant","Cofactors enabling cooperative binding not defined"]},{"year":1997,"claim":"Distinguished cAMP/PMA responsiveness between paralogs, showing a single-nucleotide difference renders CSH2 unresponsive to cAMP while retaining a shared PMA response, further explaining paralog-specific regulation.","evidence":"Transient reporter assays, EMSA, and Southwestern blotting","pmids":["9134496"],"confidence":"Medium","gaps":["Identity of the 100 kDa and 47 kDa binding proteins only inferred (CREBP/AP-1 related)","Physiological role of CSH2 cAMP-unresponsiveness unclear"]},{"year":2011,"claim":"Established C/EBPβ as a context-dependent modulator that represses the CSH2 promoter alone but activates it through the hCS-B enhancer, and confirmed differential C/EBPβ occupancy on CS-B chromatin in native placenta.","evidence":"EMSA, transient reporter assays in JEG-3 cells, and ChIP in human placental chromatin","pmids":["21737519"],"confidence":"High","gaps":["Mechanism converting repression to activation by enhancer context unresolved","Interplay with hTEF-5 not tested"]},{"year":2015,"claim":"Showed that DNA methylation and histone acetylation gate chromatin accessibility at the CSH2 enhancer and LCR, with sequential demethylation then HDAC inhibition de-repressing the gene.","evidence":"qRT-PCR, ChIP for hyperacetylated H3/H4, and luciferase reporter assays with epigenetic inhibitors in JEG-3 cells","pmids":["26634190"],"confidence":"Medium","gaps":["Specific methylated CpGs controlling accessibility not mapped","Order-dependence mechanism not explained"]},{"year":2018,"claim":"Linked CSH2 regulation to physiology by showing maternal obesity disrupts the LCR-to-promoter chromosomal architecture and that insulin partially restores it, connecting 3D locus topology to hCS output.","evidence":"Chromosome conformation capture (3C), ChIP for RNA Pol II and C/EBPβ, and qPCR across human placental samples","pmids":["29763375"],"confidence":"High","gaps":["Factor mediating obesity-induced topology change not identified in this study","Causal direction between architecture and transcription not fully separable"]},{"year":2014,"claim":"Demonstrated that CSH2 mRNA in breast cancer is not translated to protein at physiological levels, while exposing widespread non-specificity of commercial hPL antibodies.","evidence":"shRNA knockdown, multiple commercial and custom antibodies, IHC, and qRT-PCR","pmids":["24475273"],"confidence":"Medium","gaps":["Reason for translational silencing not determined","Functional consequence of breast cancer mRNA expression unknown"]},{"year":2025,"claim":"Identified PEG3/PW1 as a direct repressor binding LCR HS III-V whose occupancy tracks inversely with CSH2 expression across obesity and insulin-treated states, providing a trans-acting factor for the obesity-associated architectural changes.","evidence":"ChIP for PEG3, siRNA knockdown in JEG-3 cells, 3C, and qRT-PCR in stratified human placenta (preprint)","pmids":[],"confidence":"Medium","gaps":["Preprint, not peer-reviewed","Mechanism by which PEG3 alters LCR topology not defined"]},{"year":2025,"claim":"Explained pituitary exclusion of CSH2, showing P sequences upstream of the placental genes bind a forkhead/NF-1 repressor complex and contact LCR HS III in pituitary chromatin.","evidence":"Reporter assays in pituitary GC cells, EMSA, and 3C in human pituitary chromatin","pmids":["40362658"],"confidence":"Medium","gaps":["Direct test on CSH2 promoter (vs hPL-A) limited","How P-sequence contacts silence the placental enhancer not resolved"]},{"year":null,"claim":"The physiological function of the CSH2 protein product itself, its receptor engagement, and the basis for its translational silencing outside placenta remain uncharacterized in the available corpus.","evidence":"No timeline discovery directly assays CSH2 protein function or downstream signaling","pmids":[],"confidence":"Low","gaps":["No receptor or signaling pathway defined for the CSH2 protein","No structural information","Functional role of placental lactogen B distinct from paralogs not established"]}],"mechanism_profile":{"molecular_activity":[],"localization":[],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[3,5,6,7,9,11,12,16]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[11,12,15]}],"complexes":[],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P0DML3","full_name":"Chorionic somatomammotropin hormone 2","aliases":["Lactogen","Placental lactogen","PL"],"length_aa":217,"mass_kda":25.0,"function":"Produced only during pregnancy and is involved in stimulating lactation, fetal growth and metabolism. Does not interact with GHR but only activates PRLR through zinc-induced dimerization","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P0DML3/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CSH2","classification":"Common Essential","n_dependent_lines":521,"n_total_lines":1046,"dependency_fraction":0.4980879541108987},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CSH2","total_profiled":1310},"omim":[{"mim_id":"614468","title":"FAMILIAL COLD AUTOINFLAMMATORY SYNDROME 3; FCAS3","url":"https://www.omim.org/entry/614468"},{"mim_id":"603170","title":"TEA DOMAIN FAMILY MEMBER 3; TEAD3","url":"https://www.omim.org/entry/603170"},{"mim_id":"600220","title":"PHOSPHOLIPASE C, GAMMA-2; PLCG2","url":"https://www.omim.org/entry/600220"},{"mim_id":"171833","title":"PHOSPHATIDYLINOSITOL 3-KINASE, REGULATORY SUBUNIT 1; PIK3R1","url":"https://www.omim.org/entry/171833"},{"mim_id":"150200","title":"CHORIONIC SOMATOMAMMOTROPIN HORMONE 1; CSH1","url":"https://www.omim.org/entry/150200"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"placenta","ntpm":3105.6}],"url":"https://www.proteinatlas.org/search/CSH2"},"hgnc":{"alias_symbol":["hCS-B","CSB","CS-2"],"prev_symbol":[]},"alphafold":{"accession":"P0DML3","domains":[{"cath_id":"1.20.1250.10","chopping":"31-209","consensus_level":"high","plddt":84.6515,"start":31,"end":209}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DML3","model_url":"https://alphafold.ebi.ac.uk/files/AF-P0DML3-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P0DML3-F1-predicted_aligned_error_v6.png","plddt_mean":82.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CSH2","jax_strain_url":"https://www.jax.org/strain/search?query=CSH2"},"sequence":{"accession":"P0DML3","fasta_url":"https://rest.uniprot.org/uniprotkb/P0DML3.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P0DML3/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DML3"}},"corpus_meta":[{"pmid":"11992261","id":"PMC_11992261","title":"PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11992261","citation_count":567,"is_preprint":false},{"pmid":"2744760","id":"PMC_2744760","title":"The human growth hormone locus: nucleotide sequence, biology, and evolution.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2744760","citation_count":425,"is_preprint":false},{"pmid":"32064351","id":"PMC_32064351","title":"Molecular mechanism of SHP2 activation by PD-1 stimulation.","date":"2020","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/32064351","citation_count":212,"is_preprint":false},{"pmid":"7785978","id":"PMC_7785978","title":"Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens.","date":"1995","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/7785978","citation_count":200,"is_preprint":false},{"pmid":"21362552","id":"PMC_21362552","title":"Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism.","date":"2011","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/21362552","citation_count":167,"is_preprint":false},{"pmid":"8524268","id":"PMC_8524268","title":"The human growth hormone gene is regulated by a multicomponent locus control region.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8524268","citation_count":150,"is_preprint":false},{"pmid":"32184441","id":"PMC_32184441","title":"Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation.","date":"2020","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/32184441","citation_count":146,"is_preprint":false},{"pmid":"10980614","id":"PMC_10980614","title":"CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10980614","citation_count":137,"is_preprint":false},{"pmid":"8577729","id":"PMC_8577729","title":"Differential functions of the two Src homology 2 domains in protein tyrosine phosphatase SH-PTP1.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8577729","citation_count":126,"is_preprint":false},{"pmid":"28167755","id":"PMC_28167755","title":"Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in PIK3CD and PIK3R1.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28167755","citation_count":98,"is_preprint":false},{"pmid":"23980151","id":"PMC_23980151","title":"Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23980151","citation_count":86,"is_preprint":false},{"pmid":"8517725","id":"PMC_8517725","title":"Plasmid-mediated AmpC-type beta-lactamase isolated from Klebsiella pneumoniae confers resistance to broad-spectrum beta-lactams, including moxalactam.","date":"1993","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/8517725","citation_count":83,"is_preprint":false},{"pmid":"26085527","id":"PMC_26085527","title":"The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas.","date":"2015","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26085527","citation_count":72,"is_preprint":false},{"pmid":"26783323","id":"PMC_26783323","title":"A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.","date":"2016","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26783323","citation_count":71,"is_preprint":false},{"pmid":"31736803","id":"PMC_31736803","title":"Gut Microbiota in Bipolar Depression and Its Relationship to Brain Function: An Advanced Exploration.","date":"2019","source":"Frontiers in psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/31736803","citation_count":63,"is_preprint":false},{"pmid":"9148898","id":"PMC_9148898","title":"Human TEF-5 is preferentially expressed in placenta and binds to multiple functional elements of the human chorionic somatomammotropin-B gene enhancer.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9148898","citation_count":61,"is_preprint":false},{"pmid":"25039348","id":"PMC_25039348","title":"Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.","date":"2014","source":"Current cancer drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/25039348","citation_count":60,"is_preprint":false},{"pmid":"21980409","id":"PMC_21980409","title":"Identification and characterization of a novel multipotent sub-population of Sca-1⁺ cardiac progenitor cells for myocardial regeneration.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21980409","citation_count":56,"is_preprint":false},{"pmid":"16702225","id":"PMC_16702225","title":"Sequence specificity of SHP-1 and SHP-2 Src homology 2 domains. Critical roles of residues beyond the pY+3 position.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16702225","citation_count":56,"is_preprint":false},{"pmid":"29117520","id":"PMC_29117520","title":"Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains.","date":"2017","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/29117520","citation_count":54,"is_preprint":false},{"pmid":"8603569","id":"PMC_8603569","title":"Interaction of the molecular weight 85K regulatory subunit of the phosphatidylinositol 3-kinase with the insulin receptor and the insulin-like growth factor-1 (IGF- I) receptor: comparative study using the yeast two-hybrid system.","date":"1996","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8603569","citation_count":51,"is_preprint":false},{"pmid":"1708334","id":"PMC_1708334","title":"Tissue-specific expression and thyroid hormone regulation of the endogenous placental growth hormone variant and chorionic somatomammotropin genes in a human choriocarcinoma cell line.","date":"1991","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1708334","citation_count":43,"is_preprint":false},{"pmid":"26687682","id":"PMC_26687682","title":"Two FGF Receptor Kinase Molecules Act in Concert to Recruit and Transphosphorylate Phospholipase Cγ.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26687682","citation_count":42,"is_preprint":false},{"pmid":"15520002","id":"PMC_15520002","title":"Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15520002","citation_count":41,"is_preprint":false},{"pmid":"34725156","id":"PMC_34725156","title":"Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/34725156","citation_count":36,"is_preprint":false},{"pmid":"8083227","id":"PMC_8083227","title":"Complex alternative splicing partially inactivates the human chorionic somatomammotropin-like (hCS-L) gene.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8083227","citation_count":35,"is_preprint":false},{"pmid":"31244092","id":"PMC_31244092","title":"Gain-of-Function SHP2 E76Q Mutant Rescuing Autoinhibition Mechanism Associated with Juvenile Myelomonocytic Leukemia.","date":"2019","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/31244092","citation_count":33,"is_preprint":false},{"pmid":"21365683","id":"PMC_21365683","title":"Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.","date":"2011","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/21365683","citation_count":31,"is_preprint":false},{"pmid":"22735814","id":"PMC_22735814","title":"Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.","date":"2012","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/22735814","citation_count":31,"is_preprint":false},{"pmid":"25227611","id":"PMC_25227611","title":"The autoinhibitory C-terminal SH2 domain of phospholipase C-γ2 stabilizes B cell receptor signalosome assembly.","date":"2014","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/25227611","citation_count":29,"is_preprint":false},{"pmid":"24642386","id":"PMC_24642386","title":"Extrapituitary growth hormone synthesis in humans.","date":"2014","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/24642386","citation_count":26,"is_preprint":false},{"pmid":"17177198","id":"PMC_17177198","title":"Structural and functional effects of disease-causing amino acid substitutions affecting residues Ala72 and Glu76 of the protein tyrosine phosphatase SHP-2.","date":"2007","source":"Proteins","url":"https://pubmed.ncbi.nlm.nih.gov/17177198","citation_count":26,"is_preprint":false},{"pmid":"25924236","id":"PMC_25924236","title":"Oncogenic mutations of thyroid hormone receptor β.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25924236","citation_count":25,"is_preprint":false},{"pmid":"28915558","id":"PMC_28915558","title":"Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915558","citation_count":25,"is_preprint":false},{"pmid":"9852052","id":"PMC_9852052","title":"Physical and functional interaction between p72(syk) and erythropoietin receptor.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9852052","citation_count":24,"is_preprint":false},{"pmid":"32395997","id":"PMC_32395997","title":"Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.","date":"2020","source":"Journal of chemical information and modeling","url":"https://pubmed.ncbi.nlm.nih.gov/32395997","citation_count":23,"is_preprint":false},{"pmid":"26475863","id":"PMC_26475863","title":"Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26475863","citation_count":22,"is_preprint":false},{"pmid":"15539800","id":"PMC_15539800","title":"Genetics and variation in phenotype in Noonan syndrome.","date":"2004","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/15539800","citation_count":21,"is_preprint":false},{"pmid":"29763375","id":"PMC_29763375","title":"Chromosomal architecture and placental expression of the human growth hormone gene family are targeted by pre-pregnancy maternal obesity.","date":"2018","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/29763375","citation_count":20,"is_preprint":false},{"pmid":"34900129","id":"PMC_34900129","title":"Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state.","date":"2021","source":"Computational and structural biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/34900129","citation_count":20,"is_preprint":false},{"pmid":"30047735","id":"PMC_30047735","title":"Mechanism of Folding and Binding of the N-Terminal SH2 Domain from SHP2.","date":"2018","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/30047735","citation_count":19,"is_preprint":false},{"pmid":"8892756","id":"PMC_8892756","title":"The enhancers of the human placental lactogen B, A, and L genes: progressive activation during in vitro trophoblast differentiation and importance of the DF-3 element in determining their respective activities.","date":"1996","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/8892756","citation_count":18,"is_preprint":false},{"pmid":"7945936","id":"PMC_7945936","title":"A TEF-1 binding motif that interacts with a placental protein is important for the transcriptional activity of the hCS-B enhancer.","date":"1994","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7945936","citation_count":17,"is_preprint":false},{"pmid":"30047727","id":"PMC_30047727","title":"Calmodulin (CaM) Activates PI3Kα by Targeting the \"Soft\" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.","date":"2018","source":"The journal of physical chemistry. B","url":"https://pubmed.ncbi.nlm.nih.gov/30047727","citation_count":16,"is_preprint":false},{"pmid":"29097261","id":"PMC_29097261","title":"Calmodulin and IQGAP1 activation of PI3Kα and Akt in KRAS, HRAS and NRAS-driven cancers.","date":"2017","source":"Biochimica et biophysica acta. Molecular basis of disease","url":"https://pubmed.ncbi.nlm.nih.gov/29097261","citation_count":16,"is_preprint":false},{"pmid":"17311589","id":"PMC_17311589","title":"Analysis of RNA species of various sizes from stationary-phase planktonic yeast cells of Candida albicans.","date":"2007","source":"FEMS yeast research","url":"https://pubmed.ncbi.nlm.nih.gov/17311589","citation_count":16,"is_preprint":false},{"pmid":"38203502","id":"PMC_38203502","title":"Consideration of SHP-1 as a Molecular Target for Tumor Therapy.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38203502","citation_count":15,"is_preprint":false},{"pmid":"36155926","id":"PMC_36155926","title":"mTORC1-GLUT1-mediated glucose metabolism drives hyperactivation of B cells in primary Sjogren's syndrome.","date":"2022","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36155926","citation_count":14,"is_preprint":false},{"pmid":"8869644","id":"PMC_8869644","title":"Regulation of protein tyrosine phosphatase 1C: opposing effects of the two src homology 2 domains.","date":"1995","source":"Protein engineering","url":"https://pubmed.ncbi.nlm.nih.gov/8869644","citation_count":14,"is_preprint":false},{"pmid":"36095215","id":"PMC_36095215","title":"Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.","date":"2022","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36095215","citation_count":14,"is_preprint":false},{"pmid":"34372761","id":"PMC_34372761","title":"Proteome profiling of human placenta reveals developmental stage-dependent alterations in protein signature.","date":"2021","source":"Clinical proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/34372761","citation_count":14,"is_preprint":false},{"pmid":"29111540","id":"PMC_29111540","title":"Transcription and regulation of hepatitis B virus genes in host sperm cells.","date":"2018","source":"Asian journal of andrology","url":"https://pubmed.ncbi.nlm.nih.gov/29111540","citation_count":13,"is_preprint":false},{"pmid":"29143727","id":"PMC_29143727","title":"Characterization of clinically isolated thymidine-dependent small-colony variants of Escherichia coli producing extended-spectrum β-lactamase.","date":"2017","source":"Journal of medical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/29143727","citation_count":13,"is_preprint":false},{"pmid":"37707543","id":"PMC_37707543","title":"Single-cell insights into development of the bovine placenta†.","date":"2024","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/37707543","citation_count":12,"is_preprint":false},{"pmid":"30633923","id":"PMC_30633923","title":"Expression of growth hormone and growth hormone receptor genes in human eye tissues.","date":"2019","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/30633923","citation_count":11,"is_preprint":false},{"pmid":"32117780","id":"PMC_32117780","title":"LRRC4 Suppresses E-Cadherin-Dependent Collective Cell Invasion and Metastasis in Epithelial Ovarian Cancer.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32117780","citation_count":11,"is_preprint":false},{"pmid":"32075097","id":"PMC_32075097","title":"PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32075097","citation_count":11,"is_preprint":false},{"pmid":"29494137","id":"PMC_29494137","title":"Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29494137","citation_count":10,"is_preprint":false},{"pmid":"31164479","id":"PMC_31164479","title":"Design and evaluation of engineered protein biosensors for live-cell imaging of EGFR phosphorylation.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31164479","citation_count":10,"is_preprint":false},{"pmid":"29407222","id":"PMC_29407222","title":"Expression of growth hormone gene in the baboon eye.","date":"2018","source":"Experimental eye research","url":"https://pubmed.ncbi.nlm.nih.gov/29407222","citation_count":9,"is_preprint":false},{"pmid":"33386150","id":"PMC_33386150","title":"Molecular interactions of the CTLA-4 cytoplasmic region with the phosphoinositide 3-kinase SH2 domains.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33386150","citation_count":9,"is_preprint":false},{"pmid":"29972810","id":"PMC_29972810","title":"Dynamic Allostery in PLCγ1 and Its Modulation by a Cancer Mutation Revealed by MD Simulation and NMR.","date":"2018","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/29972810","citation_count":9,"is_preprint":false},{"pmid":"8472847","id":"PMC_8472847","title":"Differential expression of human placental growth hormone variant and chorionic somatomammotropin genes in choriocarcinoma cells treated with methotrexate.","date":"1993","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8472847","citation_count":9,"is_preprint":false},{"pmid":"30304563","id":"PMC_30304563","title":"Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30304563","citation_count":9,"is_preprint":false},{"pmid":"34605082","id":"PMC_34605082","title":"Determining folding and binding properties of the C-terminal SH2 domain of SHP2.","date":"2021","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/34605082","citation_count":8,"is_preprint":false},{"pmid":"37468946","id":"PMC_37468946","title":"An intramolecular energetic network regulates ligand recognition in a SH2 domain.","date":"2023","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/37468946","citation_count":7,"is_preprint":false},{"pmid":"16202975","id":"PMC_16202975","title":"PI3-kinase activation by GM-CSF in endothelium is upstream of Jak/Stat pathway: role of alphaGMR.","date":"2005","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16202975","citation_count":7,"is_preprint":false},{"pmid":"24225993","id":"PMC_24225993","title":"A new mutation in the C-SH2 domain of PTPN11 causes Noonan syndrome with multiple giant cell lesions.","date":"2013","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24225993","citation_count":6,"is_preprint":false},{"pmid":"27743526","id":"PMC_27743526","title":"Activities for leptin in bovine trophoblast cells.","date":"2016","source":"Domestic animal endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27743526","citation_count":6,"is_preprint":false},{"pmid":"34768012","id":"PMC_34768012","title":"A novel likely pathogenic PLCG2 variant in a patient with a recurrent skin blistering disease and B-cell lymphopenia.","date":"2021","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34768012","citation_count":6,"is_preprint":false},{"pmid":"21737519","id":"PMC_21737519","title":"Identification of functional CCAAT/enhancer-binding protein and Ets protein binding sites in the human chorionic somatomammotropin enhancer sequences.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21737519","citation_count":6,"is_preprint":false},{"pmid":"26071582","id":"PMC_26071582","title":"Alternative splicing of placental lactogen (CSH2) in somatotroph pituitary adenomas.","date":"2015","source":"Neuro endocrinology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26071582","citation_count":5,"is_preprint":false},{"pmid":"34954235","id":"PMC_34954235","title":"The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance.","date":"2021","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34954235","citation_count":5,"is_preprint":false},{"pmid":"38043374","id":"PMC_38043374","title":"Structural insights into the activation mechanism of phosphoinositide 3-kinase alpha.","date":"2023","source":"Computational biology and chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38043374","citation_count":5,"is_preprint":false},{"pmid":"28822827","id":"PMC_28822827","title":"Host genes regulate transcription of sperm-introduced hepatitis B virus genes in embryo.","date":"2017","source":"Reproductive toxicology (Elmsford, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/28822827","citation_count":5,"is_preprint":false},{"pmid":"35367415","id":"PMC_35367415","title":"A kinetic model of phospholipase C-γ1 linking structure-based insights to dynamics of enzyme autoinhibition and activation.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35367415","citation_count":5,"is_preprint":false},{"pmid":"24475273","id":"PMC_24475273","title":"Placental lactogen is expressed but is not translated into protein in breast cancer.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24475273","citation_count":5,"is_preprint":false},{"pmid":"34143834","id":"PMC_34143834","title":"Recruitment of phospholipase Cγ1 to the non-structural membrane protein pK15 of Kaposi Sarcoma-associated herpesvirus promotes its Src-dependent phosphorylation.","date":"2021","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/34143834","citation_count":5,"is_preprint":false},{"pmid":"37265738","id":"PMC_37265738","title":"Experiment-guided molecular simulations define a heterogeneous structural ensemble for the PTPN11 tandem SH2 domains.","date":"2023","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/37265738","citation_count":5,"is_preprint":false},{"pmid":"40204880","id":"PMC_40204880","title":"Gene signatures and genotype-phenotype correlations of sensorineural hearing loss in Noonan syndrome and related RASopathies.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/40204880","citation_count":4,"is_preprint":false},{"pmid":"38928272","id":"PMC_38928272","title":"Folding and Binding Kinetics of the Tandem of SH2 Domains from SHP2.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38928272","citation_count":4,"is_preprint":false},{"pmid":"3548571","id":"PMC_3548571","title":"[hGH and molecular biology].","date":"1986","source":"Annales d'endocrinologie","url":"https://pubmed.ncbi.nlm.nih.gov/3548571","citation_count":4,"is_preprint":false},{"pmid":"35634781","id":"PMC_35634781","title":"Characterization of early and late transition states of the folding pathway of a SH2 domain.","date":"2022","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/35634781","citation_count":4,"is_preprint":false},{"pmid":"36356833","id":"PMC_36356833","title":"Regulation of CD28 binding to SH2 domains of Grb2 and PI3K by trisubstituted carboranes for T-cell activation.","date":"2022","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/36356833","citation_count":4,"is_preprint":false},{"pmid":"31481652","id":"PMC_31481652","title":"C-SH2 point mutation converts p85β regulatory subunit of phosphoinositide 3-kinase to an anti-aging gene.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31481652","citation_count":3,"is_preprint":false},{"pmid":"36682394","id":"PMC_36682394","title":"Structural characterization of the type I-B CRISPR Cas7 from Thermobaculum terrenum.","date":"2023","source":"Biochimica et biophysica acta. Proteins and proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/36682394","citation_count":3,"is_preprint":false},{"pmid":"26634190","id":"PMC_26634190","title":"Expression of Placental Members of the Human Growth Hormone Gene Family Is Increased in Response to Sequential Inhibition of DNA Methylation and Histone Deacetylation.","date":"2015","source":"BioResearch open access","url":"https://pubmed.ncbi.nlm.nih.gov/26634190","citation_count":3,"is_preprint":false},{"pmid":"32236803","id":"PMC_32236803","title":"1H, 13C, 15N chemical shift assignments of SHP2 SH2 domains in complex with PD-1 immune-tyrosine motifs.","date":"2020","source":"Biomolecular NMR assignments","url":"https://pubmed.ncbi.nlm.nih.gov/32236803","citation_count":3,"is_preprint":false},{"pmid":"40318117","id":"PMC_40318117","title":"Development of a Peptide Inhibitor Targeting the C-SH2 Domain of the SHP2 Phosphatase.","date":"2025","source":"Chembiochem : a European journal of chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/40318117","citation_count":2,"is_preprint":false},{"pmid":"37505058","id":"PMC_37505058","title":"Mechanistic insights into the allosteric inactivation mechanism of ZAP-70 induced by the hot spot W165C mutation.","date":"2023","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/37505058","citation_count":2,"is_preprint":false},{"pmid":"9134496","id":"PMC_9134496","title":"A one-nucleotide difference in a cAMP and phorbol ester response element leads to differential regulation of the human chorionic somatomammotropin A and B gene transcription.","date":"1997","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9134496","citation_count":2,"is_preprint":false},{"pmid":"37668969","id":"PMC_37668969","title":"Revealing Allostery in PTPN11 SH2 Domains from MD Simulations.","date":"2023","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/37668969","citation_count":1,"is_preprint":false},{"pmid":"36638102","id":"PMC_36638102","title":"SHP-1 tyrosine phosphatase binding to c-Src kinase phosphor-dependent conformations: A comparative structural framework.","date":"2023","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/36638102","citation_count":1,"is_preprint":false},{"pmid":"40362658","id":"PMC_40362658","title":"Evidence for Pituitary Repression of the Human Growth Hormone-Related Placental Lactogen Genes and a Role for P Sequences.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40362658","citation_count":1,"is_preprint":false},{"pmid":"41658103","id":"PMC_41658103","title":"Decoding C‑SH2 Domain/Peptide Interactions in SH2 Domain-Containing Tyrosine Phosphatase 2: A Molecular Framework for Rational Inhibitor Design.","date":"2026","source":"ACS omega","url":"https://pubmed.ncbi.nlm.nih.gov/41658103","citation_count":0,"is_preprint":false},{"pmid":"41811437","id":"PMC_41811437","title":"Directed differentiation of bovine trophoblast stem cells: A useful in vitro model for placenta development.","date":"2026","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/41811437","citation_count":0,"is_preprint":false},{"pmid":"41298965","id":"PMC_41298965","title":"Cross-species identification of conserved cell-type specific mechanisms during early placenta development in ruminants.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41298965","citation_count":0,"is_preprint":false},{"pmid":"19253854","id":"PMC_19253854","title":"[SEREX screening of human placenta antigens].","date":"2008","source":"Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition","url":"https://pubmed.ncbi.nlm.nih.gov/19253854","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.12.18.628357","title":"A Locus Control Region Generates Distinct Active Placental Lactogen And  Inactive Growth Hormone Gene Domains In Term Placenta That Are Disrupted With  Obesity","date":"2024-12-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.18.628357","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53099,"output_tokens":5754,"usd":0.122803,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13704,"output_tokens":4226,"usd":0.087085,"stage2_stop_reason":"end_turn"},"total_usd":0.209888,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"Looking through the abstracts, I need to identify papers about the canonical CSH2 gene (human chorionic somatomammotropin hormone 2, also known as hCS-B, placental lactogen B). Let me classify each paper:\n\n- Papers about SHP2/PTPN11, PI3K subunits (p85 SH2 domains), PLCγ SH2 domains, ZAP-70, SHP-1, etc. → these mention \"cSH2\" or \"C-SH2\" as abbreviations for \"C-terminal SH2 domain\" of other proteins — NOT the CSH2 gene.\n- Papers about E. coli CSH2 strain (antibiotic resistance) → alias collision, skip.\n- Papers about Candida albicans CSH2 transcript → symbol collision, skip.\n- Papers about CRISPR Cas7 Csh2 from Thermobaculum terrenum → symbol collision, skip.\n- Papers about the human CSH2/hCS-B/hPL-B gene (placental lactogen) → these are on-target.\n\nOn-target papers: [2], [6], [16], [22], [26], [31], [39], [42], [43], [51], [52], [54], [55], [60], [63], [69], [71], [72], [75], [77], [82], [87], [91], [94], [96], [97], [98], [99]\n\nNow I extract only mechanistic findings (not expression correlation, survival, or pure phenotype):\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"The CSH2 (hCS-B) gene is expressed exclusively in placental tissue (not pituitary), as determined by screening pituitary and placental cDNA libraries with gene-specific oligonucleotides. The locus contains five genes with ~95% sequence identity; hCS-B is one of four placenta-specific members of the growth hormone gene cluster on chromosome 17.\",\n      \"method\": \"cDNA library screening with gene-specific oligonucleotides; full locus sequencing (~66,500 bp)\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complete nucleotide sequencing of the locus combined with cDNA library screening using specific oligonucleotide probes, replicated across multiple libraries\",\n      \"pmids\": [\"2744760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"CSH2 (hCS-B) is expressed in placenta-derived choriocarcinoma BeWo cells (but not in JAR or JEG-3 cells, and not pituitary hGH-N), and treatment with 10 nM T3 causes a ~6-fold increase in CSH2 (and hCS-A and hGH-V) mRNA levels; cellular and secreted ~22 kDa protein is increased by T3 treatment as detected by Western blot.\",\n      \"method\": \"Oligonucleotide-specific Northern blotting of polyadenylated RNA; Western blotting of cellular and secreted protein; T3 treatment of BeWo cells\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA and protein detection with gene-specific probes plus hormonal manipulation, single lab but two orthogonal methods\",\n      \"pmids\": [\"1708334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Treatment of BeWo choriocarcinoma cells with methotrexate (MTX) differentially suppresses CSH2 (hCS-B) and hCS-A relative to hGH-V; after MTX treatment only hGH-V and minor hCS-A transcripts were detected. MTX also blunts the T3-mediated increase in hCS/hGH-V transcripts without altering T3 receptor number or affinity, indicating MTX interferes with T3 responsiveness of the CSH2 gene.\",\n      \"method\": \"Northern blotting with gene-specific oligonucleotide probes; T3 receptor binding assay; MTX treatment of BeWo cells\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gene-specific RNA detection combined with receptor binding assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"8472847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The transcriptional activity of the CSH2 (hCS-B) enhancer is mediated by two protein-binding sites, DF-3 and DF-4. Protein f (three polypeptides of ~12–21 kDa identified by UV cross-linking) binds the TEF-1-like motif within DF-4 and is important for placenta-specific activity of the hCS-B enhancer. Mutations in the TEF-1-like motif of DF-4 prevent complex f formation and greatly reduce transcriptional activity in JEG-3 cells.\",\n      \"method\": \"EMSA (electrophoretic mobility-shift assay); antibody supershift; UV cross-linking; transient expression with TKCAT constructs in JEG-3 cells\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (EMSA, UV crosslinking, functional reporter assay) in single lab\",\n      \"pmids\": [\"7945936\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CSH2 (hCS-L is the pseudogene, not CSH2; this paper concerns hCS-L) — excluded as it is about the hCS-L pseudogene, not CSH2.\",\n      \"method\": \"N/A\",\n      \"journal\": \"N/A\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Excluded — paper is about hCS-L, not CSH2\",\n      \"pmids\": [\"8083227\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The CSH2 (hCS-B) gene, along with hGH-N, requires a multicomponent locus control region (LCR) located ~15 and ~30 kb 5' of hGH-N for high-level, position-independent expression. DNase I hypersensitive sites (HS) common to both pituitary and placenta are required for placental gene expression; individually each set of HS loses physiologic control and tissue specificity, demonstrating synergistic interactions among multiple elements are needed for regulated expression of the hGH/hCS cluster including hCS-B.\",\n      \"method\": \"DNase I chromatin mapping; transgenic mouse integration of cosmid constructs; position-independence assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic mouse experiments with cosmid constructs combined with DNase I chromatin mapping, multiple independent transgenic lines tested\",\n      \"pmids\": [\"8524268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The CSH2 (hCS-B) gene enhancer activity in syncytiotrophoblast primary culture is mediated by two elements, DF-3 and DF-4. A syncytiotrophoblast-specific protein binds the 3' part of DF-4, and targeted mutation of this site abolishes DF-4 element activity. The DF-3 element of hCS-B is more active than the homologous DF-3 in hCS-A due to a single naturally occurring base mutation that reduces activity in hCS-A. Replacement of the hCS-B DF-3 with the hCS-A sequence reduces hCS-B enhancer activity. During cytotrophoblast-to-syncytiotrophoblast differentiation in primary culture, hCS enhancers (including hCS-B) are progressively activated.\",\n      \"method\": \"Transient expression in primary syncytiotrophoblast culture; EMSA; targeted site-directed mutagenesis of enhancer elements\",\n      \"journal\": \"DNA and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional mutagenesis plus EMSA and primary cell culture, single lab\",\n      \"pmids\": [\"8892756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"hTEF-5 (human TEF family transcription factor) is preferentially expressed in placenta and directly binds to multiple functional enhancer elements (TEF-binding sites) within the CSH2 (hCS-B) gene enhancer, as shown by EMSA and supershift assays. A tandemly repeated TEF-5 binding element in the hCS-B enhancer is bound cooperatively by hTEF-5. The corresponding hCS-A enhancer element is inactivated by a single naturally occurring base mutation that disrupts TEF-5 binding, explaining the differential activity of these two enhancers.\",\n      \"method\": \"EMSA; antibody supershift with anti-TEA domain monoclonal antibodies; site-directed mutagenesis; cDNA cloning and Northern blotting\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal EMSA/supershift plus mutagenesis establishing transcription factor–DNA interaction mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"9148898\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"A 7 bp cAMP- and PMA-responsive element (CRElhCS-A) upstream of hCS-A mediates cAMP/phorbol ester responses, but the homologous sequence upstream of CSH2 (hCS-B), CRElhCS-B, differs by a single nucleotide substitution and shows little or no response to cAMP. Band-shift and Southwestern assays show CRElhCS-A binds a 100 kDa and a 47 kDa protein (related to CREBP and AP-1 respectively), while CRElhCS-B binds only the 47 kDa protein. The 100 kDa protein plays a crucial role in cAMP regulation specific to the hCS-A gene, while the 47 kDa protein is involved in PMA response of both hCS-A and hCS-B genes.\",\n      \"method\": \"Transient expression assays; EMSA (band-shift); Southwestern blotting\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and Southwestern plus functional reporter assays, single lab, multiple methods\",\n      \"pmids\": [\"9134496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"CCAAT/enhancer-binding protein (C/EBP) binding sites exist in the 80 bp modulatory domain of both the CSH2 (hCS-B) and hCS-A enhancers; an Elk-1 binding site is present in the CS-A enhancer modulatory domain. C/EBPα or C/EBPβ strongly represses CSH2 promoter activity alone but stimulates promoter activity when the hCS-B enhancer is present; the homologous CS-A enhancer sequences cannot relieve this repression. ChIP assays show differential association of C/EBPβ with CS-A and CS-B gene chromatin in human placenta, including differential involvement with their respective enhancers.\",\n      \"method\": \"EMSA; transient reporter assays in JEG-3 cells; chromatin immunoprecipitation (ChIP) in human placental chromatin\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — EMSA plus functional reporter assays plus ChIP in native chromatin, multiple orthogonal methods in single study\",\n      \"pmids\": [\"21737519\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CSH2 mRNA displays an alternative splicing pattern in somatotroph pituitary adenomas. CSH2 isoform 3 is associated with a dense granulation pattern and an epithelial phenotype (high ESRP1 and E-cadherin expression) and is associated with reduced serum GH and IGF-I levels after somatostatin analog (SA) treatment, linking CSH2 splicing to treatment response.\",\n      \"method\": \"RNA sequencing (RNAseq); qRT-PCR in 65 somatotroph adenomas\",\n      \"journal\": \"Neuro endocrinology letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — RNA-seq and qRT-PCR correlation in clinical samples; no direct mechanistic experiment on the CSH2 protein itself\",\n      \"pmids\": [\"26071582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Expression of placental CSH2 (hCS-B) and hCS-A genes in JEG-3 placental tumor cells is increased >10-fold by sequential treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (azadC) followed by the histone deacetylase inhibitor trichostatin A (TSA), but not by TSA alone or by reversing the treatment order. This is accompanied by increased histone H3/H4 acetylation at the hCS 3' enhancer sequences and LCR, indicating that DNA methylation restricts chromatin accessibility at these regulatory regions required for CSH2 expression.\",\n      \"method\": \"qRT-PCR of hCS-A, CS-B, GH-V RNA; ChIP for hyperacetylated H3/H4; luciferase reporter assays with hCS promoter constructs in JEG-3 and nonplacental cells\",\n      \"journal\": \"BioResearch open access\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus RNA quantification plus functional reporter assays using epigenetic inhibitors, single lab\",\n      \"pmids\": [\"26634190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Pre-pregnancy maternal obesity disrupts the placenta-specific chromosomal architecture at the hGH/CS locus, including interactions between upstream locus control region hypersensitive sites (HS III-V) and the CSH2 (hCS-B) and hCS-A gene promoters. In lean women, chromosome conformation capture detects preferential interactions between HS III-V and hCS (but not hGH) promoters; in obese women this architecture is disrupted and HS III preferentially interacts with the hGH-N promoter. Insulin treatment in obese women with gestational diabetes partially recapitulates the lean chromosomal architecture and positively affects hCS production. Decreased hCS levels in obesity are accompanied by reduced RNA polymerase II and C/EBPβ association with hCS promoter and enhancer sequences.\",\n      \"method\": \"Chromosome conformation capture (3C) assay; ChIP for RNA Pol II and C/EBPβ; quantitative PCR for hCS RNA levels\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — 3C chromatin architecture plus ChIP plus RNA quantification across multiple human tissue samples with physiological and pharmacological conditions\",\n      \"pmids\": [\"29763375\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Silencing CSH2 by RNAi in human sperm (in a model using hamster oocytes fertilized by HBV-transfected human sperm) causes a significant decrease in transcriptional levels of HBV s and x genes in the resulting embryo, indicating that CSH2 expression in sperm/embryo positively regulates HBV gene transcription.\",\n      \"method\": \"RNAi knockdown of CSH2 in human sperm; qRT-PCR of HBV s and x gene transcription in embryos derived from in vitro fertilization\",\n      \"journal\": \"Asian journal of andrology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (RNAi + qRT-PCR), unusual experimental system, no mechanistic pathway for CSH2 action established\",\n      \"pmids\": [\"29111540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CSH2 mRNA is detectable in breast cancer cell lines and some primary carcinomas; however, when CSH1/CSH2 mRNA was efficiently suppressed by shRNA, the immunoreactive 'hPL' band detected by certain commercial antibodies was not abolished, demonstrating those antibodies are non-specific. Custom monoclonal antibodies detected hPL protein only when mRNA was increased several thousand-fold, establishing that CSH2 mRNA is present in breast cancer but is not translated into protein under normal conditions.\",\n      \"method\": \"shRNA knockdown of CSH mRNA; Western blotting with multiple polyclonal and monoclonal antibodies (commercial and custom); immunohistochemistry; qRT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — shRNA knockdown combined with orthogonal antibody validation (multiple antibodies including custom) and qRT-PCR, single lab\",\n      \"pmids\": [\"24475273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The PEG3/PW1 transcription factor binds to hypersensitive sites (HS III-V) within the hPL/CSH locus control region in CTB-like JEG-3 cells, and CSH2 (hPL-B) transcript levels increase upon PEG3 knockdown. In term placenta from obese women, PEG3 binding at placenta-specific HS IV is increased and hPL RNA levels are decreased; in obese women with insulin-treated gestational diabetes, PEG3 binding is reduced and hPL expression is increased. Chromosome conformation capture reveals distinct hPL gene domain interactions that are modified with obesity but largely reversed in O/GDM+Ins, correlating with PEG3 binding levels.\",\n      \"method\": \"ChIP for PEG3 at LCR hypersensitive sites; siRNA knockdown of PEG3 in JEG-3 cells; chromosome conformation capture (3C); qRT-PCR of hPL/CSH2 RNA levels in human placenta stratified by obesity/GDM status\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP plus functional knockdown plus 3C chromatin architecture, preprint, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"P sequences located upstream of all four placental hGH/PL genes (including CSH2/hPL-B) but not hGH-N repress hPL-A promoter activity in transfected pituitary GC cells and bind a forkhead box A1/nuclear factor-1 transcription factor complex proposed to act as a repressor in human pituitary chromatin. The LCR HS III interacts with P sequences in human pituitary chromatin as detected by chromosome conformation capture, suggesting a mechanism by which P sequences prevent CSH2 and other placental hGH/PL genes from being expressed in the pituitary.\",\n      \"method\": \"Transient transfection reporter assays in pituitary GC cells; EMSA for transcription factor binding to P sequences; chromosome conformation capture (3C) in human pituitary chromatin\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay plus EMSA plus 3C, single lab\",\n      \"pmids\": [\"40362658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In cultured bovine trophoblast cells, leptin supplementation increases CSH2 (chorionic somatomammotropin hormone 2/placental lactogen) transcript abundance at both 6 h and 24 h across all doses tested (10–250 ng/mL), while it does not affect interferon-tau (IFNT) expression or cell proliferation, indicating that leptin specifically upregulates CSH2 transcription in trophoblast cells.\",\n      \"method\": \"Graded recombinant bovine leptin treatment of cultured bovine trophoblast cells; qRT-PCR measurement of CSH2 and other transcripts; cell proliferation assay\",\n      \"journal\": \"Domestic animal endocrinology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single method (qRT-PCR) in bovine cell culture, no mechanistic pathway for leptin-CSH2 signaling defined\",\n      \"pmids\": [\"27743526\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CSH2 (hCS-B/hPL-B) encodes a placenta-specific member of the human growth hormone/chorionic somatomammotropin gene cluster whose expression is restricted to syncytiotrophoblast by a multicomponent locus control region (LCR) ~15–30 kb upstream; placenta-specific transcription is driven by a downstream enhancer whose activity depends on cooperative binding of hTEF-5 to tandem TEF-binding elements and a syncytiotrophoblast-specific factor at the DF-3/DF-4 sites, modulated by C/EBPβ binding; chromatin accessibility at the LCR and enhancer is further gated by DNA methylation and histone acetylation status; chromosomal architecture linking LCR hypersensitive sites to CSH2 promoters is disrupted by maternal obesity and can be partially restored by insulin; PEG3 binding to LCR sequences represses CSH2 expression, and P sequences upstream of CSH2 prevent its expression in the pituitary; CSH2 mRNA is present in breast cancer but is not translated into protein at physiological levels.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CSH2 (hCS-B/hPL-B) is a placenta-specific member of the human growth hormone/chorionic somatomammotropin gene cluster on chromosome 17, expressed exclusively in placental tissue and restricted from the pituitary despite ~95% sequence identity among the five clustered genes [#0]. Its high-level, position-independent expression depends on a multicomponent locus control region (LCR) located ~15 and ~30 kb 5' of hGH-N, where DNase I hypersensitive sites shared between pituitary and placenta act synergistically to enforce regulated, tissue-specific output [#5]. Placenta-specific transcription is driven by a downstream enhancer composed of DF-3 and DF-4 elements: the placenta-restricted factor hTEF-5 binds cooperatively to a tandemly repeated TEF-binding motif within DF-4, and a syncytiotrophoblast-specific protein binds the 3' portion of DF-4, with naturally occurring single-base differences from the paralogous hCS-A enhancer explaining the differential activity between the two genes [#3, #6, #7]. C/EBP\\u03b2 modulates this system, repressing the CSH2 promoter alone but stimulating it in the context of the hCS-B enhancer, and associates with CS-B chromatin in native placenta [#9]. Access to the LCR and enhancer is gated epigenetically, as combined DNA-demethylation and histone-deacetylase inhibition de-represses CSH2 with concomitant H3/H4 hyperacetylation at the 3' enhancer and LCR [#11]. The chromosomal architecture linking LCR hypersensitive sites (HS III-V) to the CSH2 promoter is physiologically regulated: it is disrupted by maternal obesity and partially restored by insulin, with PEG3/PW1 binding to the LCR repressing CSH2 and tracking inversely with hPL expression [#12, #15]. P sequences upstream of the placental genes recruit a forkhead/NF-1 repressor complex that, via LCR HS III contacts, prevents CSH2 expression in the pituitary [#16].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"Established that CSH2 is a distinct, placenta-restricted member of a highly homologous five-gene cluster, defining the central regulatory problem of how near-identical genes achieve tissue-specific expression.\",\n      \"evidence\": \"cDNA library screening with gene-specific oligonucleotides and full locus sequencing\",\n      \"pmids\": [\"2744760\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not identify the cis-elements or factors enforcing placental restriction\", \"No protein-level characterization\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Showed CSH2 is hormonally regulated and produces a ~22 kDa secreted protein, demonstrating a cellular model (BeWo) for inducible expression.\",\n      \"evidence\": \"Oligonucleotide-specific Northern and Western blotting with T3 treatment of BeWo cells\",\n      \"pmids\": [\"1708334\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of T3 responsiveness at the CSH2 locus not mapped\", \"Cell-line restriction (BeWo only) unexplained\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrated that methotrexate selectively suppresses CSH2 and blunts its T3 response without altering T3 receptor levels, indicating regulation acts at the level of locus responsiveness rather than receptor abundance.\",\n      \"evidence\": \"Northern blotting, T3 receptor binding assay, and MTX treatment of BeWo cells\",\n      \"pmids\": [\"8472847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular target of MTX interference not identified\", \"No link to specific cis-elements\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Localized placenta-specific enhancer activity to DF-3 and DF-4 elements and identified a TEF-1-like motif in DF-4 bound by protein f, establishing the first cis/trans determinants of CSH2 enhancer function.\",\n      \"evidence\": \"EMSA, UV cross-linking, supershift, and TKCAT reporter assays in JEG-3 cells\",\n      \"pmids\": [\"7945936\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of protein f not molecularly defined\", \"Syncytiotrophoblast-specific factor not yet characterized\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Defined a multicomponent LCR ~15-30 kb upstream as required for high-level, position-independent CSH2 expression, showing that multiple hypersensitive sites act synergistically rather than independently.\",\n      \"evidence\": \"DNase I chromatin mapping and transgenic mouse integration of cosmid constructs\",\n      \"pmids\": [\"8524268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-acting factors at LCR HS sites not identified\", \"Mechanism of synergy and promoter selection unresolved\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Resolved why CSH2 and hCS-A enhancers differ in strength, attributing it to a single base difference in DF-3 and a syncytiotrophoblast-specific factor at DF-4, and linked enhancer activation to cytotrophoblast-to-syncytiotrophoblast differentiation.\",\n      \"evidence\": \"Transient expression in primary syncytiotrophoblast culture, EMSA, and site-directed mutagenesis\",\n      \"pmids\": [\"8892756\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Syncytiotrophoblast-specific factor identity unknown\", \"Differentiation signal driving enhancer activation not defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Identified hTEF-5 as a placenta-enriched factor binding cooperatively to a tandem TEF element in the CSH2 enhancer, providing a molecular basis for differential enhancer activity via a TEF-5-disrupting mutation in hCS-A.\",\n      \"evidence\": \"EMSA, anti-TEA-domain supershift, mutagenesis, and cDNA cloning/Northern blotting\",\n      \"pmids\": [\"9148898\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"hTEF-5 not the sole syncytiotrophoblast determinant\", \"Cofactors enabling cooperative binding not defined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Distinguished cAMP/PMA responsiveness between paralogs, showing a single-nucleotide difference renders CSH2 unresponsive to cAMP while retaining a shared PMA response, further explaining paralog-specific regulation.\",\n      \"evidence\": \"Transient reporter assays, EMSA, and Southwestern blotting\",\n      \"pmids\": [\"9134496\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the 100 kDa and 47 kDa binding proteins only inferred (CREBP/AP-1 related)\", \"Physiological role of CSH2 cAMP-unresponsiveness unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established C/EBP\\u03b2 as a context-dependent modulator that represses the CSH2 promoter alone but activates it through the hCS-B enhancer, and confirmed differential C/EBP\\u03b2 occupancy on CS-B chromatin in native placenta.\",\n      \"evidence\": \"EMSA, transient reporter assays in JEG-3 cells, and ChIP in human placental chromatin\",\n      \"pmids\": [\"21737519\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism converting repression to activation by enhancer context unresolved\", \"Interplay with hTEF-5 not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed that DNA methylation and histone acetylation gate chromatin accessibility at the CSH2 enhancer and LCR, with sequential demethylation then HDAC inhibition de-repressing the gene.\",\n      \"evidence\": \"qRT-PCR, ChIP for hyperacetylated H3/H4, and luciferase reporter assays with epigenetic inhibitors in JEG-3 cells\",\n      \"pmids\": [\"26634190\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific methylated CpGs controlling accessibility not mapped\", \"Order-dependence mechanism not explained\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked CSH2 regulation to physiology by showing maternal obesity disrupts the LCR-to-promoter chromosomal architecture and that insulin partially restores it, connecting 3D locus topology to hCS output.\",\n      \"evidence\": \"Chromosome conformation capture (3C), ChIP for RNA Pol II and C/EBP\\u03b2, and qPCR across human placental samples\",\n      \"pmids\": [\"29763375\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Factor mediating obesity-induced topology change not identified in this study\", \"Causal direction between architecture and transcription not fully separable\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated that CSH2 mRNA in breast cancer is not translated to protein at physiological levels, while exposing widespread non-specificity of commercial hPL antibodies.\",\n      \"evidence\": \"shRNA knockdown, multiple commercial and custom antibodies, IHC, and qRT-PCR\",\n      \"pmids\": [\"24475273\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reason for translational silencing not determined\", \"Functional consequence of breast cancer mRNA expression unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified PEG3/PW1 as a direct repressor binding LCR HS III-V whose occupancy tracks inversely with CSH2 expression across obesity and insulin-treated states, providing a trans-acting factor for the obesity-associated architectural changes.\",\n      \"evidence\": \"ChIP for PEG3, siRNA knockdown in JEG-3 cells, 3C, and qRT-PCR in stratified human placenta (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint, not peer-reviewed\", \"Mechanism by which PEG3 alters LCR topology not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Explained pituitary exclusion of CSH2, showing P sequences upstream of the placental genes bind a forkhead/NF-1 repressor complex and contact LCR HS III in pituitary chromatin.\",\n      \"evidence\": \"Reporter assays in pituitary GC cells, EMSA, and 3C in human pituitary chromatin\",\n      \"pmids\": [\"40362658\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct test on CSH2 promoter (vs hPL-A) limited\", \"How P-sequence contacts silence the placental enhancer not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The physiological function of the CSH2 protein product itself, its receptor engagement, and the basis for its translational silencing outside placenta remain uncharacterized in the available corpus.\",\n      \"evidence\": \"No timeline discovery directly assays CSH2 protein function or downstream signaling\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No receptor or signaling pathway defined for the CSH2 protein\", \"No structural information\", \"Functional role of placental lactogen B distinct from paralogs not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [],\n    \"localization\": [],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [3, 5, 6, 7, 9, 11, 12, 16]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [11, 12, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":7,"faith_pct":85.71428571428571}}